Becton Dickinson & Co (BDX) shareholders
BDXNYSESurgical & Medical Instruments & ApparatusFiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 13/3017% above fair value
$215.71+1.19 (+0.55%)
Close on Nov 12, 2026Market cap $58.76BP/E 65.2Yield 1.93%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
278M of 272M shares
Institutional holders
1,434
139 new, 151 sold out
Net institutional buying
16M
In Q2 2026
Insider trades, 12 months
0 buys · 22 sales
Net sold $3.38M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 22,774,866 | 7.90% | 13G (passive) amendment | Dec 31, 2023 |
| Vanguard Capital Management | 21,397,756 | 7.51% | 13G (passive) | Mar 31, 2026 |
| Vanguard Portfolio Management | 15,388,359 | 5.40% | 13G (passive) | Mar 31, 2026 |
| State Street Corporation | 15,014,710 | 5.40% | 13G (passive) | Jun 30, 2026 |
| First Eagle Investment Management, LLC | 14,138,027 | 5.10% | 13G (passive) | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of BDX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| First Eagle Investment Management, LLC | 27,630,670 | 10.14% | $4.18B | +15,702,559 | 3.47% |
| BlackRock, Inc. | 24,592,166 | 9.03% | $3.72B | −1,561,245 | 0.06% |
| Vanguard Capital Management LLC | 17,987,834 | 6.60% | $2.72B | −502,776 | 0.06% |
| State Street Corp | 15,000,064 | 5.51% | $2.27B | +1,177,256 | 0.07% |
| Vanguard Portfolio Management LLC | 14,974,136 | 5.50% | $2.27B | −343,106 | 0.10% |
| Invesco Ltd. | 8,898,488 | 3.27% | $1.35B | −1,275,839 | 0.11% |
| Massachusetts Financial Services Co /Ma/ | 8,650,967 | 3.18% | $2.48B | −450,487 | 0.79% |
| Geode Capital Management, LLC | 8,141,586 | 2.99% | $1.23B | +1,034,323 | 0.07% |
| Franklin Resources Inc | 7,011,592 | 2.57% | $1.06B | +1,648,627 | 0.23% |
| Wellington Management Group Llp | 6,357,986 | 2.33% | $962.15M | −257,244 | 0.17% |
| Greenhaven Associates Inc | 5,681,708 | 2.09% | $859.81M | New | 9.93% |
| Norges Bank | 4,169,523 | 1.53% | $630.97M | New | 0.06% |
| Price T Rowe Associates Inc /Md/ | 3,907,969 | 1.43% | $591.39M | −511,255 | 0.06% |
| T. Rowe Price Investment Management, Inc. | 3,722,952 | 1.37% | $563.40M | −5,962,319 | 0.37% |
| American Century Companies Inc | 3,676,534 | 1.35% | $556.37M | +270,617 | 0.25% |
| Charles Schwab Investment Management Inc | 3,398,203 | 1.25% | $515.29M | +74,076 | 0.07% |
| Morgan Stanley | 3,319,590 | 1.22% | $502.35M | −701,082 | 0.03% |
| Clearbridge Investments, LLC | 3,232,819 | 1.19% | $489.22M | −907,223 | 0.40% |
| Bank Of America Corp /De/ | 3,138,786 | 1.15% | $474.99M | +470,340 | 0.03% |
| JPMorgan Chase & Co | 2,835,692 | 1.04% | $440.07M | −734,632 | 0.02% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 1,434 | 278M | 100.0% | 139 / 545 | 547 / 151 | 46M | 30M |
| Q1 2026 | 1,473 | 263M | 96.5% | 133 / 589 | 521 / 191 | 59M | 37M |
| Q4 2025 | 1,549 | 278M | 100.0% | 219 / 455 | 675 / 120 | 38M | 22M |
| Q3 2025 | 1,483 | 264M | 97.0% | 142 / 583 | 556 / 161 | 34M | 29M |
| Q2 2025 | 1,520 | 260M | 95.4% | 164 / 554 | 598 / 238 | 39M | 39M |
| Q1 2025 | 1,611 | 260M | 95.4% | 136 / 608 | 620 / 131 | 22M | 20M |
| Q4 2024 | 1,627 | 260M | 95.5% | 204 / 547 | 644 / 130 | 22M | 23M |
| Q3 2024 | 1,578 | 262M | 96.1% | 127 / 567 | 627 / 117 | 41M | 16M |
| Q2 2024 | 1,586 | 259M | 95.0% | 113 / 623 | 591 / 107 | 19M | 36M |
| Q1 2024 | 1,602 | 279M | 100.0% | 144 / 595 | 617 / 115 | 29M | 18M |
| Q4 2023 | 1,594 | 268M | 98.5% | 190 / 499 | 657 / 124 | 31M | 19M |
| Q3 2023 | 1,554 | 257M | 94.4% | 109 / 545 | 589 / 114 | 15M | 13M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
816 funds held BDX in Q2 2026, 47% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of BDX | Value | % of fund | As of |
|---|---|---|---|---|---|
| First Eagle Global Fund | 9,151,995 | 3.36% | $1.52B | 1.99% | Jul 31, 2026 |
| Vanguard Total Stock Market Index Fund | 8,747,261 | 3.21% | $1.32B | 0.06% | Jun 30, 2026 |
| Vanguard 500 Index Fund | 7,136,026 | 2.62% | $1.08B | 0.06% | Jun 30, 2026 |
| Vanguard Mid-Cap Index Fund | 5,970,167 | 2.19% | $903.47M | 0.40% | Jun 30, 2026 |
| iShares Core S&P 500 ETF | 3,789,927 | 1.39% | $573.53M | 0.06% | Jun 30, 2026 |
| Fidelity 500 Index Fund | 3,643,849 | 1.34% | $536.08M | 0.06% | May 31, 2026 |
| Putnam Large Cap Value Fund | 3,064,012 | 1.12% | $507.46M | 0.92% | Jul 31, 2026 |
| Vanguard Equity Income Fund | 2,901,351 | 1.07% | $439.06M | 0.67% | Jun 30, 2026 |
| Vanguard Value Index Fund | 2,620,600 | 0.96% | $396.58M | 0.16% | Jun 30, 2026 |
| T. Rowe Price Capital Appreciation Fund | 2,012,183 | 0.74% | $304.50M | 0.43% | Jun 30, 2026 |
| State Street(R) Health Care Select Sector SPDR(R) ETF | 1,946,609 | 0.71% | $294.58M | 0.73% | Jun 30, 2026 |
| Vanguard Mid-Cap Value Index Fund | 1,769,753 | 0.65% | $267.82M | 0.72% | Jun 30, 2026 |
| Vanguard Dividend Appreciation Index Fund | 1,558,991 | 0.57% | $258.20M | 0.20% | Jul 31, 2026 |
| State Street(R) SPDR(R) S&P(R) Dividend ETF | 1,515,922 | 0.56% | $229.40M | 1.07% | Jun 30, 2026 |
| Vanguard Institutional Index Fund | 1,496,005 | 0.55% | $226.39M | 0.06% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Thomas E. Polen Jr | Chairman, CEO and President, Director | 110,163 | 0.04% | Nov 9, 2026 |
| Michael Feld | EVP, Chief Revenue Officer | 19,568 | 0.01% | Oct 27, 2026 |
| Vitor Roque | EVP & Chief Financial Officer | 8,041 | 0.00% | Sep 3, 2026 |
| Roland Goette | EVP and President, EMEA | 16,635 | 0.01% | Aug 12, 2026 |
| Bilal Muhsin | EVP & President Connected Care | 41,359 | 0.02% | Jul 6, 2026 |
| Michael David Garrison | EVP & Pres Med.Essntl&BioPharm | 13,172 | 0.00% | Jun 25, 2026 |
| Manish Sinha | EVP and Chief People Officer | 8,806 | 0.00% | Jun 22, 2026 |
| Peter Menziuso | EVP and President, BDI | 0 | – | Jun 2, 2026 |
| Shana Carol Neal | EVP and Chief People Officer | 23,966 | 0.01% | Apr 6, 2026 |
| Lanesha Minnix | EVP and General Counsel | 0 | – | Mar 17, 2026 |
| Pamela L. Spikner | SVP Controller & CAO | 3,323 | 0.00% | Mar 4, 2026 |
| Massimiliano Urbini | EVP & Chief ISC Officer | 4,133 | 0.00% | Feb 6, 2026 |
| David Shan | EVP and Chief ISC Officer | 8,926 | 0.00% | Jan 6, 2026 |
| Christopher DelOrefice | EVP & Chief Financial Officer | 27,227 | 0.01% | Dec 1, 2025 |
| Pavan Kumar Mocherla | EVP & President, Greater Asia | 5,055 | 0.00% | Dec 1, 2025 |
| Richard Byrd | EVP & President Interventional | 13,183 | 0.00% | Dec 1, 2025 |
| Michelle Quinn | EVP and General Counsel | 7,303 | 0.00% | Dec 3, 2024 |
| Antoine C. Ezell | EVP, President Americas & CMO | 13,327 | 0.00% | Nov 29, 2024 |
| Carrie L. Byington | Director | 5,018 | 0.00% | Nov 10, 2026 |
| Robert Luther Huffines | Director | 1,279 | 0.00% | Nov 10, 2026 |
| Bertram L. Scott | Director | 36,763 | 0.01% | Feb 18, 2026 |
| Christopher Ian Montague Jones | Director | 24,304 | 0.01% | Feb 5, 2026 |
| Timothy M. Ring | Director | 61,445 | 0.02% | Jan 29, 2026 |
| Joanne Waldstreicher | Director | 3,391 | 0.00% | Jan 29, 2026 |
| William M. Brown | Director | 4,663 | 0.00% | Jan 29, 2026 |
| R. Andrew Eckert | Director | 10,423 | 0.00% | Jan 29, 2026 |
| Gregory Hayes | Director | 7,159 | 0.00% | Jan 29, 2026 |
| Jacqueline Wright | Director | 1,279 | 0.00% | Jan 29, 2026 |
| Jeffrey William Henderson | Director | 9,158 | 0.00% | Jan 29, 2026 |
| Claire Fraser | Director | 22,226 | 0.01% | Sep 11, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Thomas E. Polen Jr Chairman, CEO and President, Director | Nov 5, 2026 | Sale(10b5-1 plan) | −2,993 | $210.00 | $628.53K | 110,163 |
| Thomas E. Polen Jr Chairman, CEO and President, Director | Nov 5, 2026 | Returned to company | −17,246 | $210.00 | $3.62M | 113,156 |
| Thomas E. Polen Jr Chairman, CEO and President, Director | Nov 5, 2026 | Option exercise | +20,239 | $178.94 | $3.62M | 130,402 |
| Michael Feld EVP, Chief Revenue Officer | Oct 26, 2026 | Sale(10b5-1 plan) | −76 | $198.13 | $15.06K | 19,568 |
| Michael Feld EVP, Chief Revenue Officer | Sep 28, 2026 | Sale(10b5-1 plan) | −76 | $183.70 | $13.96K | 19,644 |
| Vitor Roque EVP & Chief Financial Officer | Sep 2, 2026 | Tax withholding | −190 | – | – | 8,041 |
| Michael Feld EVP, Chief Revenue Officer | Aug 26, 2026 | Sale(10b5-1 plan) | −165 | $188.49 | $31.10K | 19,720 |
| Michael Feld EVP, Chief Revenue Officer | Aug 20, 2026 | Tax withholding | −1,049 | – | – | 19,885 |
| Thomas E. Polen Jr Chairman, CEO and President, Director | Aug 13, 2026 | Option exercise | +43,278 | $167.25 | $7.24M | 153,441 |
| Thomas E. Polen Jr Chairman, CEO and President, Director | Aug 13, 2026 | Sale(10b5-1 plan) | −4,152 | $185.00 | $768.12K | 110,163 |
| Thomas E. Polen Jr Chairman, CEO and President, Director | Aug 13, 2026 | Returned to company | −39,126 | $185.00 | $7.24M | 114,315 |
| Roland Goette EVP and President, EMEA | Aug 11, 2026 | Sale | −2,438 | $180.84 | $440.89K | 14,856 |
| Michael Feld EVP, Chief Revenue Officer | Jul 27, 2026 | Sale(10b5-1 plan) | −75 | $157.13 | $11.78K | 20,934 |
| Bilal Muhsin EVP & President Connected Care | Jul 2, 2026 | Tax withholding | −1,935 | – | – | 41,359 |
| Bilal Muhsin EVP & President Connected Care | Jul 1, 2026 | Award | +14,342 | – | – | 43,294 |
| Michael Feld EVP, Chief Revenue Officer | Jun 26, 2026 | Sale(10b5-1 plan) | −75 | $152.80 | $11.46K | 21,009 |
| Michael David Garrison EVP & Pres Med.Essntl&BioPharm | Jun 24, 2026 | Sale(10b5-1 plan) | −1,100 | $145.66 | $160.23K | 13,172 |
| Michael David Garrison EVP & Pres Med.Essntl&BioPharm | Jun 10, 2026 | Sale(10b5-1 plan) | −1,100 | $151.48 | $166.63K | 14,272 |
| Thomas E. Polen Jr Chairman, CEO and President, Director | Jun 1, 2026 | Returned to company | −17,445 | $146.15 | $2.55M | 108,235 |
| Thomas E. Polen Jr Chairman, CEO and President, Director | Jun 1, 2026 | Sale(10b5-1 plan) | −2,764 | $146.35 | $404.51K | 110,163 |
| Thomas E. Polen Jr Chairman, CEO and President, Director | Jun 1, 2026 | Option exercise | +20,209 | $126.16 | $2.55M | 125,680 |
| Peter Menziuso EVP and President, BDI | Jun 1, 2026 | Award | +14,258 | – | – | 14,258 |
| Michael Feld EVP, Chief Revenue Officer | May 26, 2026 | Sale(10b5-1 plan) | −75 | $147.35 | $11.05K | 21,084 |
| Vitor Roque EVP & Chief Financial Officer | May 7, 2026 | Award | +1,721 | – | – | 8,231 |
| Michael Feld EVP, Chief Revenue Officer | Apr 27, 2026 | Sale(10b5-1 plan) | −74 | $151.94 | $11.24K | 21,159 |
| Shana Carol Neal EVP and Chief People Officer | Apr 6, 2026 | Tax withholding | −1,146 | – | – | 23,966 |
| Michael Feld EVP, Chief Revenue Officer | Mar 26, 2026 | Sale(10b5-1 plan) | −75 | $156.83 | $11.76K | 21,233 |
| Lanesha Minnix EVP and General Counsel | Mar 16, 2026 | Award | +7,492 | – | – | 7,492 |
| Pamela L. Spikner SVP Controller & CAO | Mar 2, 2026 | Award | +931 | – | – | 3,323 |
| Vitor Roque Interim CFO | Mar 2, 2026 | Award | +931 | – | – | 6,510 |
| Michael Feld EVP, Chief Revenue Officer | Feb 26, 2026 | Sale(10b5-1 plan) | −75 | $181.84 | $13.64K | 21,308 |
| Bertram L. Scott Director | Feb 18, 2026 | Sale | −953 | $182.61 | $174.03K | 36,763 |
| Joanne Waldstreicher Director | Jan 27, 2026 | Award | +1,098 | – | – | 3,391 |
| Bertram L. Scott Director | Jan 27, 2026 | Award | +1,098 | – | – | 37,716 |
| Jacqueline Wright Director | Jan 27, 2026 | Award | +1,098 | – | – | 1,279 |
| William M. Brown Director | Jan 27, 2026 | Award | +1,098 | – | – | 4,663 |
| Robert Luther Huffines Director | Jan 27, 2026 | Award | +1,098 | – | – | 1,279 |
| Carrie L. Byington Director | Jan 27, 2026 | Award | +1,098 | – | – | 5,018 |
| R. Andrew Eckert Director | Jan 27, 2026 | Award | +1,098 | – | – | 10,423 |
| Timothy M. Ring Director | Jan 27, 2026 | Award | +1,098 | – | – | 59,160 |
| Jeffrey William Henderson Director | Jan 27, 2026 | Award | +1,098 | – | – | 9,143 |
| Christopher Ian Montague Jones Director | Jan 27, 2026 | Award | +1,098 | – | – | 24,304 |
| Gregory Hayes Director | Jan 27, 2026 | Award | +1,098 | – | – | 7,159 |
| Michael Feld EVP, CRO & Pres. Life Sciences | Jan 26, 2026 | Sale(10b5-1 plan) | −75 | $202.73 | $15.20K | 16,431 |
| Pamela L. Spikner SVP Controller & CAO | Jan 21, 2026 | Tax withholding | −84 | – | – | 1,832 |
| Michael David Garrison EVP & Pres Med.Essntl&BioPharm | Jan 15, 2026 | Returned to company | −2,454 | $209.00 | $512.89K | 13,705 |
| Michael David Garrison EVP & Pres Med.Essntl&BioPharm | Jan 15, 2026 | Option exercise | +3,054 | $167.91 | $512.80K | 16,159 |
| Michael David Garrison EVP & Pres Med.Essntl&BioPharm | Jan 15, 2026 | Sale(10b5-1 plan) | −600 | $209.00 | $125.40K | 13,105 |
| Michael David Garrison EVP & Pres Med.Essntl&BioPharm | Jan 15, 2026 | Sale(10b5-1 plan) | −1,010 | $206.54 | $208.61K | 12,095 |
| David Shan EVP and Chief ISC Officer | Jan 3, 2026 | Tax withholding | −44 | – | – | 8,926 |
| Michael Feld EVP, CRO & Pres. Life Sciences | Dec 26, 2025 | Sale(10b5-1 plan) | −74 | $196.08 | $14.51K | 16,506 |
| Michael David Garrison EVP & Pres Med.Essntl&BioPharm | Dec 17, 2025 | Sale(10b5-1 plan) | −629 | $196.03 | $123.30K | 13,105 |
| Jacqueline Wright Director | Dec 1, 2025 | Award | +180 | – | – | 180 |
| Michael Feld EVP, CRO & Pres. Life Sciences | Dec 1, 2025 | Sale(10b5-1 plan) | −75 | $193.36 | $14.50K | 16,580 |
| Robert Luther Huffines Director | Dec 1, 2025 | Award | +180 | – | – | 180 |
| Pamela L. Spikner SVPController & Chief Acct Off | Nov 26, 2025 | Award | +1,234 | – | – | 1,916 |
| Richard Byrd EVP & President Interventional | Nov 26, 2025 | Award | +6,447 | – | – | 13,183 |
| Richard Byrd EVP & President Interventional | Nov 26, 2025 | Award | +2,385 | – | – | 15,568 |
| Richard Byrd EVP & President Interventional | Nov 26, 2025 | Tax withholding | −1,719 | – | – | 13,849 |
| Roland Goette EVP and President, EMEA | Nov 26, 2025 | Award | +1,906 | – | – | 16,123 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
2.98%
8M shares short
Days to cover
5.2
At 2M shares a day
Change since last report
-9.0%
From 9M shares
Short volume, 20 days
40.5%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Becton Dickinson's stock actually held short. Settlement fails (shares not delivered on time) peaked at 11,200 shares on Oct 5, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Roland Goette Officer | Nov 10, 2026 | 1,855 | $396.87K | Nov 10, 2026 | GSIP |
| Thomas E. Polen Jr Director, Officer | Nov 5, 2026 | 2,993 | $626.11K | Nov 5, 2026 | Exercise of Stock Options |
| Michael Feld Officer | Oct 26, 2026 | 76 | $15.12K | Oct 26, 2026 | Restricted Stock Units |
| Michael Feld Officer | Sep 28, 2026 | 76 | $13.97K | Sep 28, 2026 | Restricted Stock Units |
| Michael Feld Officer | Aug 26, 2026 | 165 | $31.31K | Aug 26, 2026 | Restricted Stock Units |
| Richard Byrd Former Officer | Aug 20, 2026 | 1,330 | $249.99K | Aug 20, 2026 | Exercise of Options Under a Registered Plan |
| Thomas E. Polen Jr Director, Officer | Aug 13, 2026 | 4,152 | $762.22K | Aug 13, 2026 | Exercise of Stock Options |
| Roland Goette Officer | Aug 11, 2026 | 2,438 | $440.88K | Aug 11, 2026 | GSIP |
| Shana Carol Neal Officer | Aug 3, 2026 | 1,500 | $248.43K | Aug 3, 2026 | Restricted Stock Units |
| Michael Feld Officer | Jul 27, 2026 | 75 | $11.73K | Jul 27, 2026 | Restricted Stock Units |
| Michael Feld Officer | Jun 26, 2026 | 75 | $11.35K | Jun 26, 2026 | Restricted Stock Units |
| Michael David Garrison Officer | Jun 24, 2026 | 1,100 | $158.31K | Jun 24, 2026 | Restricted Stock Units |
| Michael David Garrison Officer | Jun 10, 2026 | 1,100 | $167.24K | Jun 10, 2026 | Restricted Stock Units |
| Thomas E. Polen Jr Officer | Jun 1, 2026 | 2,764 | $406.64K | Jun 1, 2026 | Exercise of Stock Options |
| Michael Feld Officer | May 26, 2026 | 75 | $11.07K | May 26, 2026 | Restricted Stock Units |
See a number that looks wrong?